Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAI3 | P08754 | 9/20 | 0.60 |
| ▸ | GNAI1 | P63096 | 9/20 | 0.60 |
| ▸ | GNAO1 | P09471 | 8/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.47 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | ACACB | O00763 | 1/20 | 0.44 |
| ▸ | ACACA | Q13085 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24204794 | 0.90 | GNAI3 (0.51) | GNAI3GNAI1GNAO1L3MBTL1MEN1 | |
| SCHEMBL24803097 | 0.88 | L3MBTL1 (0.49) | GNAI3GNAI1GNAO1L3MBTL1MEN1 | |
| SCHEMBL24204659 | 0.86 | GNAI3 (0.48) | GNAI3GNAI1GNAO1L3MBTL1MEN1 | |
| SCHEMBL24802123 | 0.85 | GNAI3 (0.58) | GNAI3GNAI1GNAO1L3MBTL1MEN1 | |
| SCHEMBL25952563 | 0.84 | PAOX (0.50) | GNAI3GNAI1GNAO1L3MBTL1L3MBTL3 | |
| SCHEMBL13612604 | 0.83 | L3MBTL3 (0.51) | GNAI3GNAI1GNAO1L3MBTL1L3MBTL3 | |
| SCHEMBL24352087 | 0.83 | GNAI3 (0.49) | GNAI3GNAI1GNAO1L3MBTL1L3MBTL3 | |
| SCHEMBL11240 | 0.83 | L3MBTL1 (0.62) | GNAI3GNAI1GNAO1L3MBTL1MEN1 | |
| SCHEMBL12881314 | 0.83 | L3MBTL3 (0.48) | GNAI3GNAI1GNAO1L3MBTL1MEN1 | |
| SCHEMBL12881522 | 0.82 | GNAI3 (0.51) | GNAI3GNAI1GNAO1L3MBTL1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230265116-A1 | DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEONE MEDICINES I GMBH (CH) | 2023-08-24 | — | — | US | disclosed |
| US-20230265116-A1 | DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEONE MEDICINES I GMBH (CH) | 2023-08-24 | — | — | US | disclosed |
| WO-2022268052-A9 | (R) -GLUTARIMIDE CRBN LIGANDS AND METHODS OF USE | BEIGENE, LTD. (KY) | 2023-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230265116-A1 | DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | EGFR, CBL, ERBB2 | GNAI3 2001/4885GNAI1 2029/4885GNAO1 3832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.